Interactions between Oxaliplatin and Vitamin e

Oxaliplatin has a major potential interaction with Arrhythmia.

The use of oxaliplatin has been associated with QT prolongation, and ventricular arrhythmias including fatal Torsade de Pointes. Therapy with oxaliplatin should be administered cautiously in patients with congestive heart failure, bradyarrhythmias, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating oxaliplatin and monitor these electrolytes periodically during therapy. Avoid oxaliplatin in patients with congenital long QT syndrome.

vitamin E has a major potential interaction with Biliary Obstruction.

Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin E. Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions. Vitamin E is metabolized by the liver and primarily excreted in bile and feces. Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.

Oxaliplatin has a moderate potential interaction with Bleeding Disorder.

Thrombocytopenia was frequently reported with the combination of oxaliplatin and infusional 5-FU/LV. Therapy with oxaliplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation, whose marrow function is recovering from previous cytotoxic therapy, or in patients with compromised renal function. Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechia, purpura, epistaxis, hemoptysis, hematuria, and melena. Therapy with oxaliplatin should be administered cautiously in patients with compromised bone marrow reserve. Close clinical monitoring of hematopoietic function is recommended.

Oxaliplatin has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

Thrombocytopenia was frequently reported with the combination of oxaliplatin and infusional 5-FU/LV. Therapy with oxaliplatin should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation, whose marrow function is recovering from previous cytotoxic therapy, or in patients with compromised renal function. Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechia, purpura, epistaxis, hemoptysis, hematuria, and melena. Therapy with oxaliplatin should be administered cautiously in patients with compromised bone marrow reserve. Close clinical monitoring of hematopoietic function is recommended.

Oxaliplatin has a major potential interaction with Electrolyte Abnormalities.

The use of oxaliplatin has been associated with QT prolongation, and ventricular arrhythmias including fatal Torsade de Pointes. Therapy with oxaliplatin should be administered cautiously in patients with congestive heart failure, bradyarrhythmias, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating oxaliplatin and monitor these electrolytes periodically during therapy. Avoid oxaliplatin in patients with congenital long QT syndrome.

Oxaliplatin has a moderate potential interaction with Infection.

The use of oxaliplatin for injection and 5-fluorouracil/leucovorin has been associated with sepsis, neutropenic sepsis and septic shock with fatal outcomes. Therapy with oxaliplatin should be administered cautiously in patients predisposed to neutropenia. Patients should be warned to report any febrile illness.

vitamin E has a major potential interaction with Liver Disease.

Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin E. Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions. Vitamin E is metabolized by the liver and primarily excreted in bile and feces. Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.

vitamin E has a minor potential interaction with Malabsorption Syndrome.

Vitamin E is readily absorbed from the intestinal tract in the presence of bile. Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E. A water- miscible formulation of vitamin E may be better absorbed in these conditions.

Oxaliplatin has a moderate potential interaction with Myoneural Disorder.

Rhabdomyolysis, including fatal cases, has been reported during the administration of oxaliplatin. Therapy with oxaliplatin should be administered cautiously in patients with or predisposed to myopathy. Clinical monitoring is recommended during therapy with oxaliplatin and discontinuation of therapy if any signs or symptoms of rhabdomyolysis occur.

Oxaliplatin has a moderate potential interaction with Myopathy.

Rhabdomyolysis, including fatal cases, has been reported during the administration of oxaliplatin. Therapy with oxaliplatin should be administered cautiously in patients with or predisposed to myopathy. Clinical monitoring is recommended during therapy with oxaliplatin and discontinuation of therapy if any signs or symptoms of rhabdomyolysis occur.

Oxaliplatin has a moderate potential interaction with Neurological Disorders.

Oxaliplatin for injection is associated with two types of neuropathy. An acute, reversible, primarily peripheral, sensory neuropathy that is of early onset, occurring within hours or one to two days of dosing, that resolves within 14 days, and that frequently recurs with further dosing and a persistent (>14 days), primarily peripheral, sensory neuropathy that is usually characterized by paresthesias, dysesthesias, hypoesthesias, but may also include deficits in proprioception that can interfere with daily activities (e.g., writing, buttoning, swallowing, and difficulty walking from impaired proprioception). Ice (mucositis prophylaxis) should be avoided during the infusion of oxaliplatin for Injection because cold temperature can exacerbate acute neurological symptoms. Therapy with oxaliplatin should be administered cautiously in patients with or predisposed to neurologic dysfunction.

Oxaliplatin has a moderate potential interaction with Neutropenia.

The use of oxaliplatin for injection and 5-fluorouracil/leucovorin has been associated with sepsis, neutropenic sepsis and septic shock with fatal outcomes. Therapy with oxaliplatin should be administered cautiously in patients predisposed to neutropenia. Patients should be warned to report any febrile illness.

Oxaliplatin has a moderate potential interaction with Peripheral Neuropathy.

Oxaliplatin for injection is associated with two types of neuropathy. An acute, reversible, primarily peripheral, sensory neuropathy that is of early onset, occurring within hours or one to two days of dosing, that resolves within 14 days, and that frequently recurs with further dosing and a persistent (>14 days), primarily peripheral, sensory neuropathy that is usually characterized by paresthesias, dysesthesias, hypoesthesias, but may also include deficits in proprioception that can interfere with daily activities (e.g., writing, buttoning, swallowing, and difficulty walking from impaired proprioception). Ice (mucositis prophylaxis) should be avoided during the infusion of oxaliplatin for Injection because cold temperature can exacerbate acute neurological symptoms. Therapy with oxaliplatin should be administered cautiously in patients with or predisposed to neurologic dysfunction.

Oxaliplatin has a major potential interaction with Pulmonary Impairment.

Oxaliplatin has been associated with pulmonary fibrosis (<1% of study patients), which may be fatal. Caution should be exercised when administering oxaliplatin in patients with compromised pulmonary function. Patients should be instructed to immediately report symptoms of unexplained respiratory symptoms such as non-productive cough, dyspnea, crackles, or radiological pulmonary infiltrates. Close clinical monitoring of pulmonary function is recommended and oxaliplatin should be discontinued until further pulmonary investigation excludes interstitial lung disease or pulmonary fibrosis.

Oxaliplatin has a moderate potential interaction with Renal Dysfunction.

The major route of platinum elimination is renal excretion. The exposure (AUC) of unbound platinum in plasma ultrafiltrate tends to increase in renally impaired patients. The starting dose of oxaliplatin should be reduced in patients with severe renal impairment (creatinine clearance < 30 mL/min). Caution and close monitoring should be exercised when oxaliplatin is administered to patients with renal impairment.